Literature DB >> 23325312

[Therapeutic apheresis for autoimmune encephalitis: a nationwide data collection].

S Ehrlich1, C M Fassbender, C Blaes, C Finke, A Günther, L Harms, F Hoffmann, K Jahner, R Klingel, A Kraft, T Lempert, M Tesch, J Thomsen, H Topka, J Jochim, C Veauthier, W Köhler.   

Abstract

BACKGROUND: The correlation between detection of autoantibodies and the pattern and severity of symptoms in patients with encephalitis was the crucial factor for the initiation of immune therapy. The elimination of autoantibodies using therapeutic apheresis by plasma exchange (PE) and immunoadsorption (IA) is a pathophysiologically guided therapeutic approach. The aim was to evaluate the current use of PE and for the first time also of IA for patients with autoimmune encephalitis.
METHODS: A nationwide data collection was performed and the modified Rankin score (mRS) was used to evaluate the severity of neurological symptoms.
RESULTS: Data of 31 treatment courses (30 patients and 1 relapse) were documented and 22 patients were positive for autoantibodies (NMDA-R, GABA, VGKC, Hu). In 23 cases PA was performed, tryptophan IA in 7 cases and in 1 patient both methods were applied. In 67 % of the treatment courses the mRS improved and the mean mRS of all patients was 3.2 before apheresis and 2.2 after apheresis (p < 0.05). All patients who were treated with IA improved clinically from a mean mRS of 3.9 before IA to 1.9 after IA (p < 0.01).
CONCLUSIONS: For immune-mediated forms of encephalitis rapid elimination of autoantibodies with PA and IA seems to be an effective therapeutic option as part of a multimodal immune therapy and is already established in many clinics in Germany.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325312     DOI: 10.1007/s00115-012-3710-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  27 in total

Review 1.  [Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture].

Authors:  H Prüss; J Dalmau; V Arolt; K-P Wandinger
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

2.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Authors:  B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

Review 3.  Management of voltage-gated potassium channel antibody disorders.

Authors:  Michael P Merchut
Journal:  Neurol Clin       Date:  2010-11       Impact factor: 3.806

4.  Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis.

Authors:  Corinna Trebst; Paul Bronzlik; Jan T Kielstein; Bernhard M W Schmidt; Martin Stangel
Journal:  Blood Purif       Date:  2011-11-11       Impact factor: 2.614

Review 5.  NMDA receptor antibody encephalitis.

Authors:  Sarosh R Irani; Angela Vincent
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 6.  Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis.

Authors:  Klaus-Peter Wandinger; Sandra Saschenbrecker; Winfried Stoecker; Josep Dalmau
Journal:  J Neuroimmunol       Date:  2010-10-15       Impact factor: 3.478

7.  A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.

Authors:  Wolfgang Köhler; Christoph Bucka; Reinhard Klingel
Journal:  J Clin Apher       Date:  2011-11-17       Impact factor: 2.821

8.  An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis.

Authors:  S H Wong; M D Saunders; A J Larner; K Das; I K Hart
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-26       Impact factor: 10.154

9.  Treatment of myasthenia gravis by immunoadsorption of plasma.

Authors:  D Grob; D Simpson; H Mitsumoto; B Hoch; F Mokhtarian; A Bender; M Greenberg; A Koo; S Nakayama
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

10.  Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit.

Authors:  N Galldiks; C Dohmen; M Neveling; G R Fink; W F Haupt
Journal:  Neurocrit Care       Date:  2009-12       Impact factor: 3.210

View more
  5 in total

1.  Successful treatment of anti-NMDA receptor encephalitis with a prompt ovarian tumour removal and prolonged course of plasmapheresis: A case report.

Authors:  Elzbieta Rypulak; Michal Borys; Pawel Piwowarczyk; Magdalena Fijalkowska; Beata Potrec; Justyna Sysiak; Janusz Spustek; Alicja Bartkowska-Sniatkowska; Jan Kotarski; Waldemar A Turski; Konrad Rejdak; Miroslaw Czuczwar
Journal:  Mol Clin Oncol       Date:  2016-10-19

Review 2.  [Intensive care aspects of autoimmune encephalitis].

Authors:  A Günther; J Schubert; O W Witte; D Brämer
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-08-27       Impact factor: 0.840

3.  Immunoadsorption in patients with neuromyelitis optica spectrum disorder.

Authors:  Simon Faissner; Johanna Nikolayczik; Andrew Chan; Ralf Gold; Min-Suk Yoon; Aiden Haghikia
Journal:  Ther Adv Neurol Disord       Date:  2016-05-15       Impact factor: 6.570

4.  Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: a Comparative Study of Indication, Efficacy and Safety.

Authors:  Tobias Moser; Gayane Harutyunyan; Anush Karamyan; Ferdinand Otto; Carola Bacher; Vaclav Chroust; Markus Leitinger; Helmut F Novak; Eugen Trinka; Johann Sellner
Journal:  Brain Sci       Date:  2019-10-09

Review 5.  Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms.

Authors:  Sarosh R Irani; Jeffrey M Gelfand; Adam Al-Diwani; Angela Vincent
Journal:  Ann Neurol       Date:  2014-07-10       Impact factor: 10.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.